161 related articles for article (PubMed ID: 8867863)
1. Circumventing the immune response to adenovirus-mediated gene therapy.
Kass-Eisler A; Leinwand L; Gall J; Bloom B; Falck-Pedersen E
Gene Ther; 1996 Feb; 3(2):154-62. PubMed ID: 8867863
[TBL] [Abstract][Full Text] [Related]
2. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2.
Kaplan JM; St George JA; Pennington SE; Keyes LD; Johnson RP; Wadsworth SC; Smith AE
Gene Ther; 1996 Feb; 3(2):117-27. PubMed ID: 8867859
[TBL] [Abstract][Full Text] [Related]
3. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity.
Schulick AH; Vassalli G; Dunn PF; Dong G; Rade JJ; Zamarron C; Dichek DA
J Clin Invest; 1997 Jan; 99(2):209-19. PubMed ID: 9005989
[TBL] [Abstract][Full Text] [Related]
4. "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype.
Mastrangeli A; Harvey BG; Yao J; Wolff G; Kovesdi I; Crystal RG; Falck-Pedersen E
Hum Gene Ther; 1996 Jan; 7(1):79-87. PubMed ID: 8825871
[TBL] [Abstract][Full Text] [Related]
5. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy.
Moffatt S; Hays J; HogenEsch H; Mittal SK
Virology; 2000 Jun; 272(1):159-67. PubMed ID: 10873758
[TBL] [Abstract][Full Text] [Related]
6. Host responses and persistence of vector genome following intrabronchial administration of an E1(-)E3(-) adenovirus gene transfer vector to normal individuals.
Harvey BG; Hackett NR; Ely S; Crystal RG
Mol Ther; 2001 Feb; 3(2):206-15. PubMed ID: 11237677
[TBL] [Abstract][Full Text] [Related]
7. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer.
Kass-Eisler A; Falck-Pedersen E; Elfenbein DH; Alvira M; Buttrick PM; Leinwand LA
Gene Ther; 1994 Nov; 1(6):395-402. PubMed ID: 7584105
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung.
Yei S; Mittereder N; Tang K; O'Sullivan C; Trapnell BC
Gene Ther; 1994 May; 1(3):192-200. PubMed ID: 7584081
[TBL] [Abstract][Full Text] [Related]
9. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.
Holterman L; Vogels R; van der Vlugt R; Sieuwerts M; Grimbergen J; Kaspers J; Geelen E; van der Helm E; Lemckert A; Gillissen G; Verhaagh S; Custers J; Zuijdgeest D; Berkhout B; Bakker M; Quax P; Goudsmit J; Havenga M
J Virol; 2004 Dec; 78(23):13207-15. PubMed ID: 15542673
[TBL] [Abstract][Full Text] [Related]
10. Reexpression following readministration of an adenoviral vector in adult mice after initial in utero adenoviral administration.
Lipshutz GS; Flebbe-Rehwaldt L; Gaensler KM
Mol Ther; 2000 Oct; 2(4):374-80. PubMed ID: 11020353
[TBL] [Abstract][Full Text] [Related]
11. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer.
Li D; Duan L; Freimuth P; O'Malley BW
Clin Cancer Res; 1999 Dec; 5(12):4175-81. PubMed ID: 10632357
[TBL] [Abstract][Full Text] [Related]
12. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice.
Rivière C; Danos O; Douar AM
Gene Ther; 2006 Sep; 13(17):1300-8. PubMed ID: 16688207
[TBL] [Abstract][Full Text] [Related]
13. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration.
Parks R; Evelegh C; Graham F
Gene Ther; 1999 Sep; 6(9):1565-73. PubMed ID: 10490766
[TBL] [Abstract][Full Text] [Related]
14. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.
Mack CA; Song WR; Carpenter H; Wickham TJ; Kovesdi I; Harvey BG; Magovern CJ; Isom OW; Rosengart T; Falck-Pedersen E; Hackett NR; Crystal RG; Mastrangeli A
Hum Gene Ther; 1997 Jan; 8(1):99-109. PubMed ID: 8989999
[TBL] [Abstract][Full Text] [Related]
15. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.
Bessis N; GarciaCozar FJ; Boissier MC
Gene Ther; 2004 Oct; 11 Suppl 1():S10-7. PubMed ID: 15454952
[TBL] [Abstract][Full Text] [Related]
16. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy.
Stoff-Khalili MA; Rivera AA; Glasgow JN; Le LP; Stoff A; Everts M; Tsuruta Y; Kawakami Y; Bauerschmitz GJ; Mathis JM; Pereboeva L; Seigal GP; Dall P; Curiel DT
Gene Ther; 2005 Dec; 12(23):1696-706. PubMed ID: 16034451
[TBL] [Abstract][Full Text] [Related]
17. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies.
Särkioja M; Pesonen S; Raki M; Hakkarainen T; Salo J; Ahonen MT; Kanerva A; Hemminki A
Gene Ther; 2008 Jun; 15(12):921-9. PubMed ID: 18401431
[TBL] [Abstract][Full Text] [Related]
18. Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities.
Sakurai F; Kawabata K; Yamaguchi T; Hayakawa T; Mizuguchi H
Gene Ther; 2005 Oct; 12(19):1424-33. PubMed ID: 15944730
[TBL] [Abstract][Full Text] [Related]
19. Effects of adenovirus mediated gene transfer to mouse testis in vivo on spermatogenesis and next generation.
Kojima Y; Sasaki S; Umemoto Y; Hashimoto Y; Hayashi Y; Kohri K
J Urol; 2003 Nov; 170(5):2109-14. PubMed ID: 14532865
[TBL] [Abstract][Full Text] [Related]
20. Neonatal cotton rats do not exhibit destructive immune responses to adenoviral vectors.
Zepeda M; Wilson JM
Gene Ther; 1996 Nov; 3(11):973-9. PubMed ID: 8940637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
